Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Corcept Therapeutics (NQ: CORT )

35.60 +0.73 (+2.09%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Corcept Therapeutics

< Previous 1 2 3 4 Next >
Recap: Corcept Therapeutics Q4 Earnings
Corcept Therapeutics (NASDAQ:CORT) reported its Q4 earnings results on Tuesday, February 15, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
The Daily Biotech Pulse: Larimar Plunges On Extension Of Clinical Hold, ImmunityBio Gains On Positive Data, Adcom Test Awaits Avenue Therapeutics
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus ImmunityBio Says Cancer Combo Therapy Produces Positive Results In Late-Stage... 
Via Benzinga
Why Corcept Therapeutics Stock Was Up 11.6% Friday
Investors may be looking for a bargain after the company was hit with bad news this week. 
Via The Motley Fool
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers BioLine Rx (NASDAQ:BLRX) shares moved upwards by 23.65% to $2.81 during Friday's regular session. As of 12:30 EST, BioLine Rx's stock is trading at a... 
Via Benzinga
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
Exposures Product Safety
Earnings Scheduled For February 15, 2022
Companies Reporting Before The Bell • FirstService (NASDAQ:FSV) is estimated to report quarterly earnings at $1.31 per share on revenue of $1.07 billion. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 2, 2022
Upgrades Oppenheimer upgraded the previous rating for NovoCure Ltd (NASDAQ:NVCR) from Perform to Outperform. NovoCure earned $0.13 in the third quarter, compared to $0.09... 
Via Benzinga
Why Corcept Therapeutics Tanked by Almost 17% Today
A U.S. attorney is interested in the company for the wrong reasons. 
Via The Motley Fool
Topics Law Enforcement
Exposures Legal
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Virpax Pharmaceuticals (NASDAQ:VRPX) shares increased by 26.54% to $5.12 during Wednesday's regular session. Trading volume for Virpax Pharmaceuticals's... 
Via Benzinga
52 Biggest Movers From Yesterday
Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares surged 84.1% to close at $19.11 on Wednesday. Insignia Systems recently announced the commencement of a formal process to... 
Via Benzinga
35 Stocks Moving In Wednesday's Mid-Day Session
Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares jumped 79% to $18.63. Insignia Systems recently announced the commencement of a formal process to explore strategic options... 
Via Benzinga
Corcept Therapeutics Incorporated (CORT) Q3 2021 Earnings Call Transcript
CORT earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics... 
Via Benzinga
Topics Retirement
Exposures Pension
3 Buy-The-Dip Stocks To Snap Up Now
Given current market volatility, buying the dip in fundamentally sound stocks could be a smart move. Thus, the recent dips in Corcept Therapeutics, NextGen Healthcare, and Core Molding Technologies... 
Via Talk Markets
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
Corcept Therapeutics' Relacorilant Combo Therapy Shows Clinical Benefit In Ovarian Cancer
Corcept Therapeutics Incorporated (NASDAQ: CORT) has announced that data from the Phase 2 trial of relacorilant plus nab-paclitaxel were presented at the European... 
Via Benzinga
The Week Ahead In Biotech (Sept. 12-18): Calliditas FDA Decision, Adcom Review For Pfizer/BioNTech COVID-19 Vaccine, Oncology Conference And IPOs
Biotech stocks retreated in the holiday-shortened week ending Sept. 10, reversing course from the previous week. Humanigen, Inc. (NASDAQ: HGEN) was among the biggest... 
Via Benzinga
Exposures COVID-19 Product Safety
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers IVERIC bio (NASDAQ:ISEE) shares ... 
Via Benzinga
Corcept Therapeutics Incorporated (CORT) Q2 2021 Earnings Call Transcript
CORT earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 9) Adagio Therapeutics, Inc. (... 
Via Benzinga
Corcept Therapeutics Stock Drops After Disappointing Interim Data From Relacorilant Plus Nab-Paclitaxel Trial In Pancreatic Cancer
Corcept Therapeutics Incorporated (NASDAQ: CORT) has announced preliminary results from its Phase 3 RELIANT trial of relacorilant for metastatic pancreatic cancer... 
Via Benzinga
Corcept Stops Phase 2 NASH Study With Miricorilant Due To Elevated Liver Enzymes In Patients
Corcept Therapeutics Incorporated (NASDAQ: CORT) has announced interim data from the Phase 2 trial evaluating its selective cortisol modulator miricorilant in... 
Via Benzinga
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
Corcept Therapeutics Incorporated (CORT) Q1 2021 Earnings Call Transcript
CORT earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.